GE HealthCare is expected to announce Monday a $945 million cash purchase of a manufacturer

The deal, expected to be announced Monday, would give GE HealthCare greater control over a critical supply in nuclear medicine. • The substances, known as radiopharmaceuticals, help doctors detect and monitor diseases including cancer, heart conditions and neurological disorders. • PET scans depend on radioactive tracers that must be produced and delivered quickly because many have short half-lives. • The acquisition could strengthen GE HealthCare’s position in a market shaped by rising demand for advanced diagnostic imaging. • It also reflects a broader push by health care companies to secure specialized manufacturing and supply chains. Further details, including the target company’s identity and the expected closing timeline, are anticipated with the formal announcement.